Clinical Trial

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09 -> 2026-12 2026-04-23
minor Completion pushed: 2026-09 -> 2027-02 2026-04-23
Trial Details
NCT Number NCT07169851
Lead Sponsor Eli Lilly and Company
Conditions Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Enrollment 204 participants
Start Date 2025-11-28
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06